FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080643100> ?p ?o ?g. }

• W2080643100 endingPage "1713" @default.
• W2080643100 startingPage "1713" @default.
• W2080643100 abstract "<b>Objectives</b> To examine the risk of relapse and time to relapse after discontinuation of antidepressants in patients with anxiety disorder who responded to antidepressants, and to explore whether relapse risk is related to type of anxiety disorder, type of antidepressant, mode of discontinuation, duration of treatment and follow-up, comorbidity, and allowance of psychotherapy. <b>Design</b> Systematic review and meta-analyses of relapse prevention trials. <b>Data sources</b> PubMed, Cochrane, Embase, and clinical trial registers (from inception to July 2016). <b>Study selection</b> Eligible studies included patients with anxiety disorder who responded to antidepressants, randomised patients double blind to either continuing antidepressants or switching to placebo, and compared relapse rates or time to relapse. <b>Data extraction</b> Two independent raters selected studies and extracted data. Random effect models were used to estimate odds ratios for relapse, hazard ratios for time to relapse, and relapse prevalence per group. The effect of various categorical and continuous variables was explored with subgroup analyses and meta-regression analyses respectively. Bias was assessed using the Cochrane tool. <b>Results</b> The meta-analysis included 28 studies (n=5233) examining relapse with a maximum follow-up of one year. Across studies, risk of bias was considered low. Discontinuation increased the odds of relapse compared with continuing antidepressants (summary odds ratio 3.11, 95% confidence interval 2.48 to 3.89). Subgroup analyses and meta-regression analyses showed no statistical significance. Time to relapse (n=3002) was shorter when antidepressants were discontinued (summary hazard ratio 3.63, 2.58 to 5.10; n=11 studies). Summary relapse prevalences were 36.4% (30.8% to 42.1%; n=28 studies) for the placebo group and 16.4% (12.6% to 20.1%; n=28 studies) for the antidepressant group, but prevalence varied considerably across studies, most likely owing to differences in the length of follow-up. Dropout was higher in the placebo group (summary odds ratio 1.31, 1.06 to 1.63; n=27 studies). <b>Conclusions</b> Up to one year of follow-up, discontinuation of antidepressant treatment results in higher relapse rates among responders compared with treatment continuation. The lack of evidence after a one year period should not be interpreted as explicit advice to discontinue antidepressants after one year. Given the chronicity of anxiety disorders, treatment should be directed by long term considerations, including relapse prevalence, side effects, and patients’ preferences." @default.
• W2080643100 created "2016-06-24" @default.
• W2080643100 creator A5025710499 @default.
• W2080643100 date "1982-06-05" @default.
• W2080643100 modified "2023-09-26" @default.
• W2080643100 title "Contractual problems in Oxford" @default.
• W2080643100 doi "https://doi.org/10.1136/bmj.284.6330.1713" @default.
• W2080643100 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1498614" @default.
• W2080643100 hasPublicationYear "1982" @default.
• W2080643100 type Work @default.
• W2080643100 sameAs 2080643100 @default.
• W2080643100 citedByCount "0" @default.
• W2080643100 crossrefType "journal-article" @default.
• W2080643100 hasAuthorship W2080643100A5025710499 @default.
• W2080643100 hasBestOaLocation W20806431002 @default.
• W2080643100 hasConcept C118552586 @default.
• W2080643100 hasConcept C126322002 @default.
• W2080643100 hasConcept C142724271 @default.
• W2080643100 hasConcept C156957248 @default.
• W2080643100 hasConcept C204787440 @default.
• W2080643100 hasConcept C207103383 @default.
• W2080643100 hasConcept C27081682 @default.
• W2080643100 hasConcept C2778715236 @default.
• W2080643100 hasConcept C44249647 @default.
• W2080643100 hasConcept C558461103 @default.
• W2080643100 hasConcept C71924100 @default.
• W2080643100 hasConcept C95190672 @default.
• W2080643100 hasConceptScore W2080643100C118552586 @default.
• W2080643100 hasConceptScore W2080643100C126322002 @default.
• W2080643100 hasConceptScore W2080643100C142724271 @default.
• W2080643100 hasConceptScore W2080643100C156957248 @default.
• W2080643100 hasConceptScore W2080643100C204787440 @default.
• W2080643100 hasConceptScore W2080643100C207103383 @default.
• W2080643100 hasConceptScore W2080643100C27081682 @default.
• W2080643100 hasConceptScore W2080643100C2778715236 @default.
• W2080643100 hasConceptScore W2080643100C44249647 @default.
• W2080643100 hasConceptScore W2080643100C558461103 @default.
• W2080643100 hasConceptScore W2080643100C71924100 @default.
• W2080643100 hasConceptScore W2080643100C95190672 @default.
• W2080643100 hasIssue "6330" @default.
• W2080643100 hasLocation W20806431001 @default.
• W2080643100 hasLocation W20806431002 @default.
• W2080643100 hasOpenAccess W2080643100 @default.
• W2080643100 hasPrimaryLocation W20806431001 @default.
• W2080643100 hasRelatedWork W2047252483 @default.
• W2080643100 hasRelatedWork W2074274808 @default.
• W2080643100 hasRelatedWork W2170298832 @default.
• W2080643100 hasRelatedWork W2286371484 @default.
• W2080643100 hasRelatedWork W2318119155 @default.
• W2080643100 hasRelatedWork W2747332931 @default.
• W2080643100 hasRelatedWork W3017329712 @default.
• W2080643100 hasRelatedWork W3038392370 @default.
• W2080643100 hasRelatedWork W3154231528 @default.
• W2080643100 hasRelatedWork W4309666149 @default.
• W2080643100 hasVolume "284" @default.
• W2080643100 isParatext "false" @default.
• W2080643100 isRetracted "false" @default.
• W2080643100 magId "2080643100" @default.
• W2080643100 workType "article" @default.